Study of the frequencies of CYP1A1 gene polymorphisms and glutathione S- transferase mu1 gene in primary breast cancers: An update with an additional 114 cases

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 403, Issue 1-2, 1998, Pages 45-53

  Fontana, Xavier ^a   Peyrottes, Isabelle ^a   Rossi, Charlie ^a   Leblanc Talent, Pascale ^a   Ettore, Francette ^a   Namer, Moïse ^a   Bussière, Françoise ^a  

^a Lacassagne   (France)

Author keywords

Breast cancer; Carcinogenesis; CYP1A1 polymorphism; Glutathione S transferase mu1

Indexed keywords

CATHEPSIN D; CYTOCHROME P450 ISOENZYME; GLUTATHIONE TRANSFERASE;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GRADING; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CATHEPSIN D; CYTOCHROME P-450 CYP1A1; DEOXYRIBONUCLEASE HPAII; DNA, NEOPLASM; FEMALE; GENE AMPLIFICATION; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; MIDDLE AGED; POINT MUTATION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROGNOSIS; PROTEINS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEINS;

EID: 0032540937     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(98)00025-6     Document Type: Article

References (31)

1. [1] M.S. Wolff, G.W. Collman, J.C. Barrett, J. Huff, Breast cancer and environmental risk: epidemiological and experimental findings, Annu. Rev. Pharmacol. Toxicol. 36 (1996) 573-596.
2. [2] J.K. Dunnick, M.R. Elwell, J. Huff, J.C. Barrett, Chemically induced mammary gland cancer in the national toxicology program's carcinogenesis biossay, Carcinogenesis 16 (1995) 173-179.
3. [3] D. Li, M. Wang, K. Dhingra, W.N. Hittelman, Aromatic DNA adducts in adjacent tissues of breast cancer patients: clues to breast cancer etiology, Cancer Res. 56 (1996) 287-293.
4. [4] M.S. Greenblatt, W.P. Bennett, M. Hollstein, C.C. Harris, Mutations in the p53 tumor suppressor gene: clue to cancer etiology and molecular pathogenesis, Cancer Res. 54 (1994) 4855-4878.
5. [5] F.J. Gonzalez, H.V. Gelboin, Role of human cytochrome P-450s in risk assessment and susceptibility to environmentally based disease, J. Toxicol. Environ. Health 40 (1993) 289-308.
6. [6] W.R. Fields, Y. Li, A.J. Townsend, Protection by transfected glutathione S-transferase isozymes against carcinogen-induced akylation of cellular macromolecules in human MCF-7 cells, Carcinogenesis 15 (1994) 1155-1160.
7. [7] H. Raunio, K. Husgafvel-Pursiainen, S. Anttila, E. Hietanen, A. Hirvonen, O. Pelkonen, Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility - a review, Carcinogenesis 16 (1995) 2209-2213.
8. [8] N. Drakoulis, I. Cascorbi, J. Brockmöller, C.R. Gross, I. Roots, Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3‰-flanking region, Clin. Invest. 72 (1994) 240-248.
9. [9] S.J. Garte, J. Trachman, F. Crofts, P. Toniolo, J. Buxbaum, S. Bayo, E. Taioli, Distribution of composite CYP1A1 genotypes in Africans, African-Americans and caucasians, Hum. Hered. 46 (1996) 121-127.
10. [10] S. Hayashi, J. Watanabe, K. Nakachi, K. Kawajiri, Genetic linkage of lung cancer-associated Msp1 polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene, J. Biochem. 110 (1991) 407-411.
11. [11] F. Crofts, G. Cosma, D. Currie, E. Taioli, P. Toniolo, S.J. Garte, A novel CYP1A1 gene polymorphism in African-Americans, Carcinogenesis 14 (1993) 1729-1731.
12. [12] I. Cascorbi, J. Brockmöller, I. Roots, A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility, Cancer Res. 56 (1996) 4965-4969.
13. [13] T. Okada, K. Kawashima, S. Fukushi, T. Minakuchi, S. Nishimura, Association between a cytochrome P450 CYPIA1 genotype and incidence of lung cancer, Pharmacogenetics 4 (1994) 333-340.
14. [14] C.B. Ambrosone, J.L. Freudenheim, S. Graham, J.R. Marshall, J.E. Vena, J.R. Brasure, R. Laughlin, T. Nemoto, A.M. Michalek, A. Harrington, T.D. Ford, P.G. Shields, Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk, Cancer Res. 55 (1995) 3483-3485.
15. [15] E. Taioli, J. Trachman, X. Chen, P. Toniolo, S.J. Garte, A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women, Cancer Res. 55 (1995) 3757-3758.
16. [16] V.L. Ross, P.G. Board, G.C. Webb, Chromosomal mapping of the human mu class glutathione S-transferases to 1 p13, Genomics 18 (1993) 87-91.
17. [17] S. Zhong, A.H. Wyllie, D. Barnes, C.R. Wolf, N.K. Spurr, Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer, Carcinogenesis 14 (1993) 1821-1824.
18. [18] J.K. Wiencke, K.T. Kelsey, R.A. Lamela, W.A. Toscano Jr., Human glutathione S-transferase deficiency as a marker of susceptibility to epoxide-induced cytogenetic damage, Cancer Res. 50 (1990) 1585-1590.
19. [19] T.C. Shea, G. Claflin, K.E. Comstock, B.J. Sanderson, N.A. Burstein, E.J. Keenan, B. Mannervik, W.D. Henner, Glutathione transferase activity and isoenzyme composition in primary human breast cancers, Cancer Res. 50 (1990) 6848-6853.
20. [20] X. Fontana, I. Peyrotte, E. Valente, C. Rossi, F. Ettore, M. Namer, F. Bussière, Glutathione S-transferase mu1 (GSTM1): gène de susceptibilité du cancer du sein, Bull. Cancer 84 (1997) 35-40.
21. [21] D.A. Bell, J.A. Taylor, D.F. Paulson, C.N. Robertson, J.L. Mohler, G.W. Lucier, Genetic risk and carcinogen exposure: a common inherited effect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer, J. Natl. Cancer Inst. 85 (1993) 1159-1164.
22. [22] E. Taioli, F. Crofts, J. Trachman, S. Bayo, P. Toniolo, S.J. Garte, Racial differences in CYP1A1 genotype and function, Toxicol. Lett. 77 (1995) 357-362.
23. [23] S.J. London, A.K. Daly, K.S. Fairbrother, C. Holmes, C.L. Carpenter, W.C. Navidi, J.R. Idle, Lung cancer risk in African-Americans in relation to a race-specific CYP1A1 polymorphism, Cancer Res. 55 (1995) 6035-6037.
24. [24] C. Bouchardy, H. Wikman, S. Benhamou, A. Hirvonen, P. Dayer, K. Husgafvel-Pursiainen, CYP1A1 genetic polymorphisms, tobacco smoking and lung cancer risk in a French caucasian population, Biomarkers 2 (1997) 131-134.
25. [25] D. Spink, H. Eugster, D. Lincoln, 17-beta estradiol hydroxylation catalyzed by human cytochrome P450 IA1, Arch. Biochem. Biophys. 293 (1992) 342-348.
26. [26] P. Vineis, Molecular epidemiology: low-dose carcinogens and genetic susceptibility, Int. J. Cancer 71 (1997) 1-3.
27. [27] C. Kiyohara, T. Hirohata, S. Inutsuka, The relationship between aryl hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene, Jpn. J. Cancer Res. 87 (1996) 18-24.
28. [28] I. Persson, I. Johansson, M. Ingelman-Sundberg, In vitro kinetics of two human CYP1A1 variants enzymes suggested to be associated with interindividual differences in cancer susceptibility, Biochem. Biophys. Res. Commun. 231 (1997) 227-230.
29. [29] J.K. Wiencke, M.R. Wrensch, R. Miike, Z. Zuo, K.T. Kelsey, Population-based study of glutathione S-transferase mu gene deletion in adult glioma cases and controls, Carcinogenesis 7 (1997) 1431-1433.
30. [30] C. Vaury, R. Lainé, P. Noguiez, P. de Coppet, C. Jaulin, F. Praz, D. Pompon, M. Amor-Guéret, Human glutathione S-transferase m1 null genotype is associated with a high inducibility of cytochrome P450 1A1 gene transcription, Cancer Res. 55 (1995) 5520-5523.
31. [31] L. Tomatis, J. Huff, I. Hertz-Picciotto, D.P. Sandler, J. Bucher, P. Boffetta, O. Axelson, A. Blair, J. Taylor, L. Stayner, J.C. Barrett, Avoided and avoidable risks of cancer, Carcinogenesis 18 (1) (1997) 97-105.